Elevated Systolic Blood Pressure Predicts Motor Outcomes in Parkinson’s Disease--A Retrospective Analysis of the CALM-PD Trial (S5.004)

• DOI: 10.1212/wnl.86.16_supplement.s5.004
• Publication Date: 2023-12-07T09:29:56Z
• Authors: Christina Lineback; Roger Albin; Nicolaas Bohnen; Vikas Kotagal; The Parkinson Stu...

Objective: To explore the role of elevated blood pressure as a risk factor for motor decline in Parkinson disease (PD). Background: Microvascular brain pathology occurs aging, where it associates with subclinical impairments. We have previously reported that white matter hyperintensities (WMHs) correlate more rapid rate feature accrual PD. Advanced age and higher systolic are two key factors development WMHs may influence progressive burden Design/Methods: Using data from multicenter CALM-PD trial, we conducted retrospective analysis to determine if mean (SBP) predicted cohort patients early PD (n=275). For each subject, SBP was calculated all study visits between weeks 0 102. Multiple linear regression used control age, gender, duration, treatment arm, dose, open label levodopa dose. Motor outcomes were determined by calculating change UPDRS III "on" scores week 4 Results: The overall model showed significant predictor effect score (F=4.87, p<0.0001). Higher associated greater (t=1.97, p=0.049). Worsening also male gender (t=2.22, p=0.027), receiving lowest dose drug (t=4.57, p<0.0001) randomization pramipexole rather than (t=2.38, p=0.018). Conclusion: Elevated is marker longitudinal This association reflect on WMH formation or other unmeasured vascular factors. Alternatively, be trait sources pathological progression Supported P30KL2AG024824. Data made available through Study Group Retrospective Datamining Project.